Bilirubinemia May Protect Against Severe Retinopathy of Prematurity in Extremely Preterm Infants: Study
USA: Bilirubinemia might offer protection against the severity of retinopathy of prematurity (ROP), a recent study has concluded.
The study published in Pediatric Research has revealed intriguing findings regarding bilirubinemia and its potential protective effect against the severity of retinopathy of prematurity (ROP) in infants born at 29 weeks gestational age or earlier. The research provides new insights into how bilirubin levels might influence the development of ROP, a serious eye condition affecting premature infants.
Retinopathy of prematurity is a condition where abnormal blood vessels grow in the retina of premature infants, potentially leading to vision impairment or even blindness. It is influenced by several factors, including oxygen levels, gestational age, and overall health of the infant.
Bilirubin is recognized as an antioxidant, but observational studies on its role in influencing the incidence and severity of retinopathy of prematurity (ROP) in premature infants have yielded conflicting results. Considering this, Srujana Rallabandi, University of California, San Francisco, CA, USA, and Sanjiv B. Amin, Wayne State University, Detroit, MI, USA, hypothesized that the degree of bilirubinemia is inversely associated with oxidative stress-mediated retinopathy of prematurity.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.